Leerink Partnrs Has Negative Outlook of VYGR FY2024 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Leerink Partnrs lowered their FY2024 earnings per share (EPS) estimates for shares of Voyager Therapeutics in a research note issued on Tuesday, November 12th. Leerink Partnrs analyst L. Nsongo now expects that the company will post earnings per share of ($0.66) for the year, down from their previous forecast of ($0.44). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($1.27) per share. Leerink Partnrs also issued estimates for Voyager Therapeutics’ Q4 2024 earnings at ($0.13) EPS, FY2025 earnings at ($0.67) EPS, FY2026 earnings at ($0.49) EPS, FY2027 earnings at ($1.16) EPS and FY2028 earnings at ($0.45) EPS.

A number of other equities analysts have also recently commented on VYGR. Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a report on Thursday. Wedbush reduced their price target on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a report on Thursday. Leerink Partners assumed coverage on Voyager Therapeutics in a report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target for the company. Finally, StockNews.com cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, November 10th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $17.00.

Voyager Therapeutics Price Performance

Shares of NASDAQ VYGR opened at $6.22 on Friday. The stock has a market capitalization of $339.18 million, a price-to-earnings ratio of 8.76 and a beta of 0.89. The business has a 50-day moving average of $6.63 and a 200-day moving average of $7.52. Voyager Therapeutics has a fifty-two week low of $5.71 and a fifty-two week high of $11.72.

Insider Activity

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the sale, the insider now directly owns 86,001 shares in the company, valued at approximately $500,525.82. The trade was a 6.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.53% of the stock is owned by company insiders.

Institutional Investors Weigh In On Voyager Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Armistice Capital LLC raised its position in shares of Voyager Therapeutics by 11.3% in the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after buying an additional 528,000 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Voyager Therapeutics by 27.8% in the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after purchasing an additional 702,030 shares during the last quarter. Farallon Capital Management LLC grew its stake in shares of Voyager Therapeutics by 77.4% in the first quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock worth $21,339,000 after purchasing an additional 1,000,000 shares during the last quarter. Great Point Partners LLC bought a new stake in shares of Voyager Therapeutics in the second quarter worth $12,668,000. Finally, Erste Asset Management GmbH bought a new stake in shares of Voyager Therapeutics in the third quarter worth $6,192,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.